We serve Chemical Name:5-[(4-nitrophenyl)methyl]-1H-1,2,4-triazol-3-amine CAS:90349-93-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-[(4-nitrophenyl)methyl]-1H-1,2,4-triazol-3-amine
CAS.NO:90349-93-2
Synonyms:5-(4-NITROBENZYL)-4H-1,2,4-TRIAZOL-3-AMINE;5-(4-nitro-benzyl)-1H-[1,2,4]triazol-3-ylamine
Molecular Formula:C9H9N5O2
Molecular Weight:219.20000
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:547.9ºC at 760 mmHg
Density:1.483
Index of Refraction:1.697
PSA:113.41000
Exact Mass:219.07600
LogP:1.99030
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5-(4-NITROBENZYL)-4H-1,2,4-TRIAZOL-3-AMINE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-(4-nitro-benzyl)-1H-[1,2,4]triazol-3-ylamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-(4-NITROBENZYL)-4H-1,2,4-TRIAZOL-3-AMINE Use and application,5-(4-nitro-benzyl)-1H-[1,2,4]triazol-3-ylamine technical grade,usp/ep/jp grade.
Related News: Many branded versions of drugs are currently more expensive in China than in other major markets. They could now be subjected to a centralized procurement program where manufacturers will have to go through a bidding process to get the right to supply drugs to public hospitals, the National Health Commission said in a document published on late Friday. 5-[(4-nitrophenyl)methyl]-1H-1,2,4-triazol-3-amine manufacturer Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037. 5-[(4-nitrophenyl)methyl]-1H-1,2,4-triazol-3-amine supplier All of China��s provinces and territories have now been touched by the outbreak. 5-[(4-nitrophenyl)methyl]-1H-1,2,4-triazol-3-amine vendor All of China��s provinces and territories have now been touched by the outbreak. 5-[(4-nitrophenyl)methyl]-1H-1,2,4-triazol-3-amine factory Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.